Therapeutic options in response to the COVID-19 pandemic are urgently needed. A keyword in these worldwide effortsis ‘repurposing’ – the development of approved antiviral drugs as candidates for COVID-19. Chloroquine (CQ) and its hydroxyl analog hydroxychloroquine (HCQ) are showing preliminary inhibitory effects against COVID-19 and apparent efficacy in clinical studies. We propose a variant of the repurposing strategy: developing single enantiomers of these old racemic drugs. We call for urgently pursuing the chiral switches of HCQ and/or CQ for the treatment of COVID-19.
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 / D’Acquarica, Ilaria; Agranat, Israel. - In: DRUG DISCOVERY TODAY. - ISSN 1359-6446. - 25:7(2020), pp. 1121-1123. [10.1016/j.drudis.2020.04.021]
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19
D’Acquarica, Ilaria
Primo
;
2020
Abstract
Therapeutic options in response to the COVID-19 pandemic are urgently needed. A keyword in these worldwide effortsis ‘repurposing’ – the development of approved antiviral drugs as candidates for COVID-19. Chloroquine (CQ) and its hydroxyl analog hydroxychloroquine (HCQ) are showing preliminary inhibitory effects against COVID-19 and apparent efficacy in clinical studies. We propose a variant of the repurposing strategy: developing single enantiomers of these old racemic drugs. We call for urgently pursuing the chiral switches of HCQ and/or CQ for the treatment of COVID-19.| File | Dimensione | Formato | |
|---|---|---|---|
|
D'acquarica_Chiral-switches_2020.pdf
solo gestori archivio
Note: COVID-19-related article immediately available in PubMed Central and other publicly funded repositories
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
353.2 kB
Formato
Adobe PDF
|
353.2 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
D'Acquarica_postprint_Chiral-switches _2020.pdf
Open Access dal 02/05/2021
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
221.63 kB
Formato
Unknown
|
221.63 kB | Unknown | Visualizza/Apri PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
